Dosage of naloxone
AssigneeDevelco Pharma Schweiz AG
InventorsHelene Rey, Olaf Mundszinger, Isabelle Golfier, Silvia Jakob, Oliver Rusch
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition comprising a μ-receptor antagonist as an active substance, wherein the antagonist is prepared in an extended release formulation. The composition is intended for the treatment of patients with opioid-induced constipation, wherein the dosage of the μ-receptor agonist is independent of the opioid dosage. The preferred dosage of the μ-receptor antagonist of the composition is equivalent to a daily dosage of 20-70 mg naloxone.
Claims20
A method comprising:
- administering a composition comprising an extended release formulation of a μ-receptor antagonist in a dosage equivalent to a daily dosage of 20 mg to 70 mg of naloxone to a subject receiving an opioid treatment,
- wherein the μ-receptor antagonist is administered independently of the opioid treatment.
A composition comprising an opioid and a μ-receptor antagonist, wherein the μ-receptor antagonist is not naloxone.
A composition comprising an opioid and a μ-receptor antagonist, wherein the opioid is not oxycodone.
A composition comprising an opioid and a μ-receptor antagonist, wherein there is greater than about a 2.1:1 molar ratio of opioid to μ-receptor antagonist.
A composition comprising an opioid and a μ-receptor antagonist, wherein there is less than about a 2:1 molar ratio of opioid to μ-receptor antagonist.
Dependencies are inferred from the claim text.